EFFIX
LIVE

Serial Number

79443342

Owner

WuXi Biologics (Hangzhou) Co., Ltd.

Attorney

Eric Lamb

Filing Date

Jun 26, 2025

Add to watchlist:

No watchlists yet
View on USPTO

EFFIX Trademark

Serial Number: 79443342

EFFIX is a trademark filed by WuXi Biologics (Hangzhou) Co., Ltd. on June 26, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

WuXi Biologics (Hangzhou) Co., Ltd.

1st-4th Floor, Building 3, Heke Technology Center,

Entity Type: 16

Trademark Details

Filing Date

June 26, 2025

Registration Date

Not Registered

Goods & Services

Consulting services in the field of technology development in the field of protein-related biological research; research and development of new products for others; scientific research and development; biochemical research and analysis; pharmaceutical products development services; pharmaceutical research services; research in the field of synthetic biology; development of pharmaceutical preparations and medicines; biomedical research services; scientific research and development services in the field of gene expression systems.

Biological preparations, other than for medical or veterinary purposes, for use in industry and science in connection with genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial purposes in scientific research and for use in pharmaceutical research; preparations of microorganisms, other than for medical and veterinary use; bacterial preparations, other than for medical and veterinary use; bacteriological preparations, other than for medical and veterinary use for use in industry and science in connection with genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial purposes in scientific research and for use in pharmaceutical research; biochemical reagents for scientific use; biochemical reagents, other than for medical use; collagen for industrial purposes; proteins for use in manufacture; protein for use in manufacture, namely, recombinant proteins expressed via microbial systems; proteins for industrial purposes; chemical additives for use in the manufacture of cosmetics; proteins for the food industry; proteins for use in the manufacture of cosmetics.

Biological preparations for medical purposes for the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; preparations of microorganisms for medical use; pharmaceutical preparations for use in the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; medicines for human purposes for use in the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; cells for medical use; bacterial preparations for medical use; all the above-mentioned goods not intended to be used in the veterinary field.

Custom manufacture of nanobodies, enzymes, cytokine, antibody fragments, virus-like particles, pDNA, antigens peptides, recombinant proteins, and vectors for others; processing and treatment of chemical reagents, namely, custom synthesis and manufacture of reagents for scientific or medical research use in the field of drug conjugation; custom manufacturing of cosmetics; custom manufacturing of pharmaceuticals; custom manufacture of biological preparations; custom manufacturing of biomedical preparations; custom manufacturing of biotechnology drugs; custom manufacturing of antibody drugs; custom manufacturing of biopharmaceuticals

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 10, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 10, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Sep 10, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Sep 10, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 10, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 8, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 8, 2026 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 8, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 8, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 8, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 8, 2026 COAR
REFUSAL PROCESSED BY IB
Apr 9, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 20, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 20, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 17, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 16, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 16, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 15, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 15, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 12, 2026 REPR